Altimmune (ALT) had its price target lowered by B. Riley Financial, Inc. from $18.00 to $13.00. They now have a "buy" rating on the stock.
Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away [Seeking Alpha]
Altimmune Inc (ALT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Fortification [Yahoo! Finance]
Altimmune (ALT) had its "market perform" rating reaffirmed by William Blair.
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates [Yahoo! Finance]